EXEMBOL*
Manufacturer Details
MITSUBHI PHARMA*
MITSUBHI PHARMA INC
medinfo@mitsubhi-pharma.eu
Compositions:
Argatroban Monohydrate 100mg/ml intrvenous infusion,
|
Strength
|
Rate
|
Packing Style
|
|
100mg/ml
|
0.00
|
2.5ml vial intravenous infusion
|
List of Related Indications:
- Heparin induced Thtombocytopenia
List Of Drugs:
- Argatroban Monohydrate- Anti-coagulant- (BNF-2015)
Indication Type Description:
Indication:
Heparin induced thrombocytopenia
Contra-Indications:
Cautions-
Risk of bleeding including severe
Dosages/ Overdosage Etc:
Indication-
Heparin induced thrombocytopenia
Dosage-
Adult over 18 years
by continuous intravenous infusion
initially 2 microgram/kg/minute , adjusted according to
activated partial thromboplastin time,
upto maximum 10 micrograms/kg/minute
maximum duration of treatment 14 days
Note-
For dose in cardiac surgery . percutaneous coronary
intervention, or critically ill patients, consult product literature
Note-
When initiating concomittant warfarin treatment.
argatroban dose should be temporarily reduced to
2 microgram/kg/minute and INR measured after 4-6 hours,
warfarin should be initiated as intended maintenance dose
(do not giveloading dose of warfarin )
consult product literature for further details
Pregnancy and lactation:
Pregnancy-
Manufacturer advices avoid unless essential-
limited information available
Breast feeding -
Avoid- no information available
